Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department

2 de agosto de 2026 actualizado por: Selda Ateş Beşirik, Burdur Mehmet Akif Ersoy University

The Effect of Vibration and ShotBlocker on Pain and Fear Levels During Intramuscular Injection in Children in the Emergency Department: A Randomized Controlled Trial

This prospective study is planned as a randomized controlled study. The aim of this study is to investigate the effects of vibration and the ShotBlocker method on pain and fear levels in children during intramuscular injection in the emergency department.

Descripción general del estudio

Descripción detallada

Emergency departments are among the clinical areas where invasive procedures frequently encountered by children are performed. Intramuscular injections are one of the most common procedures performed on children in the emergency department, and they can cause pain and fear, leading to negative experiences for children. In the literature, it is stated that nurses should use pharmacological and non-pharmacological methods in pain and fear management in painful procedures. Evidence-based studies are needed to show the effectiveness of non-pharmacological methods in reducing pain during invasive procedures and to investigate the effects of easy-to-apply methods on pain.

This prospective study is planned as a randomized controlled study. The aim of this study is to investigate the effects of vibration and the ShotBlocker method on pain and fear levels in children during intramuscular injection in the emergency department.

The study will be conducted in three groups (Vibration, ShotBlocker, and Control), and a total of 120 children will be enrolled, with 40 participants in each group. The primary outcome will be pain intensity. The sample size was determined using an a priori power analysis performed with G*Power version 3.1.9.7. The calculation was based on a one-way analysis of variance (ANOVA) with three groups, an alpha level of 0.05, 80% statistical power (1-β = 0.80), and a Cohen's effect size (f) of 0.30. The analysis indicated that a minimum of 111 participants would be required. Considering potential participant attrition and missing data, the sample size was increased to 120 participants, with 40 children allocated to each group (Vibration Group, n = 40; ShotBlocker Group, n = 40; and Control Group, n = 40).

Data were collected through face-to-face interviews using three forms: the "Data Collection Form," the "Wong-Baker FACES Pain Scale," and the "Children's Fear Scale." Data Collection: Before starting the study, parents of children meeting the sample selection criteria will be briefly informed about the purpose of the study, and written consent will be obtained for their participation. Then, data collection tools will be administered. Forms will be collected through face-to-face interviews. After a child is selected, the nurse working at the institution will administer the intramuscular injection to the child, while routine injections will be given to the control group children. No intervention will be performed. The nurse will apply vibration to the vibration group children. In the vibration group, vibration will begin 30 seconds before the injection, and no vibration will be applied during the 10-second waiting phase while the nurse performs the intramuscular injection. In the shotblocker group children, the nurse will position the device between the injection site and the heel prick blood sample.

Shotblocker: This is a plastic device. No needle is inserted into the patient. The researcher will monitor the child's pain and fear levels during this time. Parents and observers will be asked to rate their fear/anxiety levels on the CFS scale before, during, and after the procedure, while children will be asked to do the same before and after. The child's post-procedure pain level (WB-FACES scale) will be assessed by the child themselves, as well as by the parent and observer. The scales will be evaluated independently and simultaneously, and the results will be recorded on a form.

No invasive procedure will be performed on the child. All these procedures will take approximately 5-10 minutes.

Tipo de estudio

Intervencionista

Inscripción (Estimado)

120

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Selda ATES BESIRIK, PhD. Study Principal Investigator, Assist. Prof.
  • Número de teléfono: +905543683323
  • Correo electrónico: seldaates07@gmail.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Burdur, Turquía (Türkiye)
        • Reclutamiento
        • Burdur Mehmet Akif Ersoy University
        • Contacto:
          • Selda ATES BESIRIK, PhD.
          • Número de teléfono: +905543683323
          • Correo electrónico: seldaates07@gmail.com

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Niño

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Volunteering of the child and parent to participate in the study,
  • Children the ages between 5-10,
  • Having intramuscular (IM) injection.

Exclusion Criteria:

  • Communication problem,
  • Children with any chronic illness,
  • Taking any medication that has an analgesic effect at least 6 hours before applying.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Vibration Group
Vibration was applied to the children in this group before and during the intramuscular Injection procedure.
The vibration device was operated for 30 seconds with reference to previous studies. While the vibration continued, the nurse with a needle.Then, the vibration device continued to work in the waiting phase for 10 seconds. The vibration device was removed from routine intramuscular Injection procedure.
Otros nombres:
  • Vibration Group
Experimental: Shotblocker Group
ShotBlocker was applied to the children in this group before and during the intramuscular Injection procedure.
The protruding surface of the Shotblocker was placed on the procedure site. While applying pressure on the skin through the Shotblocker, the nurse performed with the needle through the opening in the center of the Shotblocker. During the 10-second waiting phase, the Shotblocker was kept at the procedure site with the same pressure. Then Shotblocker was removed from the skin and routine capillary intramuscular injection procedure was performed.
Otros nombres:
  • Shotblocker Group
Sin intervención: Control Group
In this group, child received routine intramuscular Injection procedure.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Escala de calificación del dolor de caras de Wong-Baker
Periodo de tiempo: A través de la finalización dolorosa del procedimiento, un promedio de 10 minutos
En el estudio, las evaluaciones del nivel de dolor, las autoevaluaciones de los niños, las evaluaciones de los padres y las evaluaciones del investigador se realizaron mediante la escala WB-FACES. Esta escala fue desarrollada por Donna Wong y Connie Morain Baker en 1988. La escala se califica entre 0-10 puntos. Una cara sonriente en el extremo izquierdo simboliza "sin dolor" (0 muy feliz/sin dolor) y el dolor aumenta de izquierda a derecha. Por otro lado, una cara llorando en el extremo derecho simboliza un "dolor insoportable" (10 'duele más'). A medida que aumentan los números en este sistema de puntuación, las expresiones faciales también cambian en referencia a un aumento en los niveles de dolor.
A través de la finalización dolorosa del procedimiento, un promedio de 10 minutos

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Children's Fear Scale
Periodo de tiempo: Through painful procedure completion, an average of 10 minutes.
CFS is used for measuring the child's anxiety level. CFS is a scale which makes an evaluation from 0 to 4 consisting of five facial expressions drawn to show expressions that vary from neutral expression (0=no anxiety) to scared face (4=severe anxiety).
Through painful procedure completion, an average of 10 minutes.

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Selda A ATES BESIRIK, PhD., Burdur Mehmet Akif Ersoy University

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

2 de agosto de 2026

Finalización primaria (Estimado)

30 de octubre de 2026

Finalización del estudio (Estimado)

16 de noviembre de 2026

Fechas de registro del estudio

Enviado por primera vez

2 de agosto de 2026

Primero enviado que cumplió con los criterios de control de calidad

2 de agosto de 2026

Publicado por primera vez (Actual)

6 de agosto de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de agosto de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de agosto de 2026

Última verificación

1 de agosto de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

SÍ

Descripción del plan IPD

Individual participant data that underlie the results reported in this study, after deidentification, will be shared with researchers who provide a methodologically sound proposal.

Tipo de información de apoyo para compartir IPD

  • PROTOCOLO DE ESTUDIO
  • SAVIA
  • CIF
  • CÓDIGO_ANALÍTICO
  • RSC

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir